stockrow
Friday 6 November 2026
Export CPIX’s income statement to Excel — free account
Cumberland Pharmaceuticals Inc.
CPIX Healthcare Drug Manufacturers Specialty & Generic
Cumberland Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, up 17.6% from fiscal 2024.
- Revenue
- −98.5%
- EPS
- −480.0%
- Free cash flow
- −82.8%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
5.24
0.23
+4.59%
Follow CPIX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 33 | 41 | 29 | 34 | 37 | 36 | 42 | 40 | 38 | 45 | 31 | +3.4% | — | — | — | — | |
| Gross margin, % | 81.96 | 82.09 | 79.50 | 78.42 | 76.89 | 75.51 | 78.29 | 84.66 | 82.61 | 85.02 | 110.49 | +3.1 pt | ||||||
| EBT | (1) | (4) | (11) | (9) | (7) | (6) | (6) | (6) | (6) | (3) | (7) | +8.6% | ||||||
| EBT margin, % | (4.04) | (9.42) | (36.82) | (27.02) | (17.55) | (15.46) | (13.29) | (15.89) | (17.08) | (6.31) | (23.38) | (2.3) pt | ||||||
| Net income | (1) | (8) | (7) | (4) | (3) | (4) | (6) | (6) | (6) | (3) | (11) | +12.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 2.03 | 2.59 | 1.88 | 2.23 | 2.47 | 2.41 | 2.88 | 2.77 | 2.69 | 3.00 | 2.09 | +4.4% | |||||
| Earnings | (0.06) | (0.50) | (0.45) | (0.23) | (0.22) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) | (0.73) | +13.7% | ||||||
| Cash flow | 0.04 | (0.03) | 0.20 | 0.20 | 0.36 | 0.43 | 0.58 | 0.43 | (0.04) | 0.33 | 0.05 | +28.4% | ||||||
| Capex | (0.13) | (0.09) | (0.27) | (0.07) | (0.14) | (0.02) | (0.14) | (0.03) | (0.01) | (0.01) | (0.01) | (23.1%) | ||||||
| Free cash flow | (0.10) | (0.13) | (0.07) | 0.13 | 0.22 | 0.40 | 0.44 | 0.39 | (0.06) | 0.32 | 0.04 | n/m | ||||||
| Book value | 4.50 | 4.02 | 3.56 | 3.32 | 3.09 | 2.86 | 2.47 | 2.05 | 1.60 | 1.65 | 1.14 | (10.5%) | ||||||
| Shares, m | 16 | 16 | 16 | 15 | 15 | 15 | 15 | 14 | 14 | 15 | 15 | (1.0%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 2.88 | 2.73 | 3.21 | 2.31 | 1.19 | 1.93 | 0.80 | 0.67 | 0.88 | 1.33 | 2.41 | 1.8 | ||||||
| P/B | 1.30 | 1.76 | 1.69 | 1.55 | 0.95 | 1.63 | 0.94 | 0.90 | 1.48 | 2.41 | 4.41 | 1.5 | ||||||
| EV/Sales | 1.49 | 1.75 | 2.66 | 2.05 | 0.96 | 1.63 | 0.72 | 0.54 | 0.81 | 1.30 | 2.62 | 1.4 | ||||||
| EV/FCF | (31.45) | (35.13) | (67.04) | 34.60 | 10.90 | 9.78 | 4.74 | 3.77 | (38.68) | 12.21 | 142.36 | (9.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 1 | (1) | 3 | 3 | 5 | 6 | 8 | 6 | (1) | 5 | 1 | +27.1% | |||||
| Capex | (2) | (1) | (4) | (1) | (2) | 0 | (2) | 0 | 0 | 0 | 0 | (23.9%) | ||||||
| Free cash flow | (2) | (2) | (1) | 2 | 3 | 6 | 6 | 6 | (1) | 5 | 1 | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 51 | 51 | 31 | 26 | 24 | 26 | 17 | 8 | 5 | 0 | (2) | (43.1%) | |||||
| Net debt | (46) | (40) | (16) | (9) | (9) | (11) | (3) | (6) | (3) | (6) | (4) | (20.0%) | ||||||
| Shareholders’ equity | 73 | 64 | 56 | 51 | 47 | 43 | 36 | 29 | 23 | 25 | 17 | (11.4%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (1.02) | (8.55) | (6.76) | (3.26) | (3.32) | (3.88) | (6.28) | (7.19) | (8.24) | (3.72) | (16.70) | (2.7) pt | |||||
| ROIC | (3.31) | (10.79) | (17.75) | (13.73) | (10.46) | (15.22) | (10.94) | (25.17) | (20.24) | (9.51) | (34.23) | (6.2) pt | ||||||
| ROE | (1.26) | (11.64) | (11.65) | (6.63) | (6.82) | (7.84) | (14.18) | (19.25) | (25.02) | (12.05) | (48.76) | (10.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 82 | 84 | 80 | 94 | 90 | 83 | 85 | 91 | 91 | 93 | — | +1.4% | |||||
| Revenue/emp, $m | 0.40 | 0.49 | 0.37 | 0.37 | 0.42 | 0.43 | 0.49 | 0.43 | 0.42 | 0.48 | — | +1.9% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Cumberland Pharmaceuticals Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BGM BGM Group Ltd. | $125.7M | 148× | 44.9× | −2.59% (below 0%: shrinking) | −85.71% (below 0%: shrinking) | +3.00% (above 0%: growing) | 7.12% | 0.00% | Compare |
| CRDL Cardiol Therapeutics Inc. | $111.8M | — (loss-making) | — (loss-making) | — | n/m | +10.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ORGO Organogenesis | $108.1M | — (loss-making) | — (loss-making) | −69.87% (below 0%: shrinking) | n/m | −2,048.82% (below 0%: shrinking) | 51.83% | (64.87%) | Compare |
| CPIX Cumberland Pharmaceuticals Inc. | $75.1M | — (loss-making) | — (loss-making) | −98.46% (below 0%: shrinking) | n/m | −82.78% (below 0%: shrinking) | 100.00% | (1,898.20%) | |
| TLPH Talphera, Inc. | $52.4M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −33.11% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CTOR Citius Oncology, Inc. | $46.5M | — (loss-making) | — | — | n/m | 0.00% | 67.07% | (583.53%) | Compare |
| ZYBT Zhengye Biotechnology Holding Limited | $41.0M | — | — | — | — | −69.31% (below 0%: shrinking) | — | — | Compare |
| INCR InterCure Ltd. | $39.1M | 6.2× | — (loss-making) | −6.53% (below 0%: shrinking) | n/m | +389.50% (above 0%: growing) | 32.04% | 0.00% | Compare |
| SCYX SCYNEXIS, Inc. | $32.8M | — (loss-making) | — (loss-making) | −8.56% (below 0%: shrinking) | n/m | −98.60% (below 0%: shrinking) | 100.00% | (3,308.51%) | Compare |
| Median of peers | $49.5M | — | — | −8.56% | — | −16.55% | 51.83% | 0.00% |
Pay and ownership Proxy statement filed 9 March 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.24m | 979.85k | 134.92 |
| 2024 | 1.11m | 979.27k | 46.02 |
| 2023 | 979.68k | 952.53k | 34.79 |
| 2022 | 583.44k | 897.50k | 43.69 |
| 2021 | 1.53m | 872.63k | 90.68 |
Ownership
Directors and executive officers, together
42.07%
A. J. Kazimi
38.43%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement